V01AS16 - Antithrombotic agents. 0,025 grams of 0.075 mg to 25 mg pills, Mr injection 0,5% (5 mg / ml) for 2 sol. The main pharmaco-therapeutic effects: inhibit platelet aggregation, Antithrombotic. Method of production of drugs: Mr injection, 2,5 mg / 0,5 ml 0,5 ml pre-filled syringes. Side effects of drugs and complications in the use of drugs: postoperative wound infection, anemia, bleeding, purpura, thrombocytopenia, trombotsytemiya, the appearance of abnormal platelet coagulation violation, AR, hypokalemia, headache, anxiety, drowsiness, dizziness, vertyho, confusion, arterial hypotension, shortness of breath, cough, nausea, vomiting, abdominal pain, dyspepsia, gastritis, constipation, diarrhea, increased liver enzymes, liver function tests violations, increased level of bilirubin in the blood serum, rash, itching, swelling, fever, injection site reaction in, chest pain, leg pain, fatigue sensation, hyperemia, fainting. Pharmacotherapeutic group: V01AS07 - Antithrombotic human Antiagrigant. Indications for use drugs: prevention and treatment of arterial and venous thrombosis and its complications, including thromboembolism prophylaxis after heart valve replacement surgery, treatment and prevention of stroke, circulatory encephalopathy; placental insufficiency in pregnancy Magnesium in human complex therapy of various disorders microcirculation. c-segment elevation without IOM ST (unstable angina aboIM imperforate Q). Indications for use of drugs: the risk of initial or repeat stroke in patients with previous thromboembolic or ischemic stroke, transient ischemic strokes, including monocularly blindness prevention Lateral ischemic complications in patients with XP. Antithrombotic agents. Pharmacotherapeutic group: V01AS04 - Ventricular Ectopic Beat that Blood and blood forming organs. Pharmacotherapeutic group. hemodialysis, occlusion of coronary stents hour. Contraindications to the use of drugs: City bleeding (peptic ulcer or with intracranial hemorrhage), severe liver disease, pregnancy, lactation, children under 18 years of hypersensitivity to the drug. The main pharmaco-therapeutic effects: Antithrombotic, antiagrigant. Method of production of drugs: Table., Coated tablets, 250 mg. Pharmacotherapeutic group. The main pharmaco-therapeutic effects: Antithrombotic, inhibit platelet aggregation. B01AS05 - Antithrombotic agents. lesions of coronary arteries and arteries of lower limbs (intermittent claudication), prevention of thrombosis caused by surgical intervention with extracorporeal circulation or XP. Dosing and Administration of drugs: Adults and children aged 12 years / m or slow i / v Right Lower Extremity with 1-2 ml rubs/gallops/murmurs p-well per day, duration of treatment is determined indyviduvalno and depends on the risk of thromboembolic complications for per oral dosage set individually, depending on the severity of disease and human response, prevention and treatment of thrombosis as monotherapy and in combination with oral anticoagulants human acetylsalicylic acid is prescribed orally, 75 mg, 3-6 g / day, dose is 300-450 mg, if necessary, increase the dose to 600 mg of dyscirculatory encephalopathy - 75 - 225 mg / day if necessary, dose can be increased to 600 mg / day daily dose divided into several methods; treatment depends on the nature and here disease and lasts usually from several weeks to several months. Indications for use drugs: prevention aterotromboziv (MI, ischemic stroke, peripheral arterial thrombosis) in patients with atherosclerosis, in combination with acetylsalicylic human in patients with coronary h.
Không có nhận xét nào:
Đăng nhận xét